CRLF2 and acute lymphoblastic leukemia: CRLF2 rearrangements (14.3% of PED DS ALL, 7.3% of all PED patients; Supplemental Tables S2 and S3) were also common in the PED DS ALL cohort but absent in the AYA DS ALL and AYA ML-DS cohorts.